9/19/2013 6:39:39 AM
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, presented collaborative data at the Cancer Advance Conference at Harvard Medical School from proof-of-principle imaging studies using tilmanocept-Cy3, a fluorescent-labeled agent from the Company’s Manocept™ platform, utilizing technical principle underlying Navidea’s FDA-approved lymphatic mapping product, Lymphoseek® (technetium 99m tilmanocept) Injection.
Help employers find you! Check out all the jobs and post your resume.
comments powered by